Yilmaz, YusufOzturk, OguzhanAlandab, Yesim OzenSenates, EbubekirColak, YasarDoganay, Hamdi LeventCoskunpinar, Ender2024-04-242024-04-2420131590-8658https://doi.org/10.1016/j.dld.2012.08.017https://hdl.handle.net/11468/15335Background: Osteopontin is a secreted phosphorylated glycoprotein that is expressed by a variety of cell types and that mediates numerous and diverse biological functions. Osteopontin knockout mice are protected from obesity-induced hepatic steatosis. In the present study, we sought to investigate whether serum osteopontin concentrations are associated with liver histology in patients with nonalcoholic fatty liver disease. Methods: Serum levels of osteopontin were measured by enzyme-linked immunosorbent assay in 179 Well-characterized patients with nonalcoholic fatty liver referred for liver histology and 123 control subjects. Results: Serum osteopontin levels were markedly higher in patients with nonalcoholic fatty liver disease than in controls (p < 0.001). Multivariable analysis showed that osteopontin levels were strongly and independently associated with both portal inflammation (beta = 0.294, p < 0.01) and serum aminotransferase levels (aspartate aminotransferase: beta = 0.295, p < 0.01; alanine aminotransferase; beta = 0.285, p < 0.01). Conclusion: In summary, these data demonstrate that serum levels of osteopontin are elevated in nonalcoholic fatty liver disease and are a significant independent predictor of portal inflammation in this clinical entity. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessBiomarkerInflammationNonalcoholic Fatty Liver DiseaseOsteopontinPortal InflammationArticle4515862WOS:0003159300000122-s2.0-848716074832299555310.1016/j.dld.2012.08.017Q1Q2